Dr. Mehrdad Ghahramani, MD

Dr. Ghahramani practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Ghahramani's NPI, 1851718951, was assigned on March 26, 2014. Dr. Ghahramani graduated from Ross University School of Medicine in 2013. Dr. Ghahramani holds Florida license ME144783.

Dr. Ghahramani's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Ghahramani's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Ghahramani is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ghahramani practices, 2 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Ghahramani's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Ghahramani is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Ghahramani's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists aortic atherosclerois, atrial fibrillation and flutter, cardiomyopathy, chronic hypertension, chronic skin ulcer, coronary artery disease, heart blockage and heart failure among the conditions Dr. Ghahramani treats.

CMS data shows 2,407 Medicare services from Dr. Ghahramani across 15 procedure codes in 2024, for 1,371 Medicare patients. Medicare paid $102,530 for them.

CMS counts 1,371 Medicare patients who saw Dr. Ghahramani in 2024. The largest group is 65 to 74, with 570 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ghahramani's median patient age at 71, with 50% women.

In 2024, Dr. Ghahramani wrote 648 Medicare Part D claims for 163 patients. 88% of them were for generic drugs. CMS names the drug for 585 of them, across 18 drugs with 11 or more claims each, at $76,325 in total drug cost. In 2023, CMS named 587 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Ghahramani for performance year 2024. Dr. Ghahramani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ghahramani as offering telehealth.

Dmand AI links 18 papers to Dr. Ghahramani, published from 2016 to 2020. 2019 was the busiest year, with 6. The most frequent topics are Attitude of Health Personnel, Kidney Transplantation and Pennsylvania. Dr. Ghahramani has published most often in Am J Cardiol. Dr. Ghahramani's most frequent co-authors are Mohammed Ruzieh, MD, Gerald V. Naccarelli, MD and Morgan Kiyoko Moroi, MD.

CMS Open Payments shows 16 general payments to Dr. Ghahramani from 3 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 93% of the total. Boston Scientific Corporation paid the most, $336.

Dr. Ghahramani graduated from Ross University School of Medicine in 2013. Dr. Ghahramani is a member of ACC.

Dr. Ghahramani is in network with 12 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.